Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
4 "Fei Wang"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Lung and Thoracic cancer
EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
Weiguang Gu, Hua Zhang, Yiyu Lu, Minjing Li, Shuang Yang, Jianmiao Liang, Zhijian Ye, Zhihua Li, Minhong He, Xiaoliang Shi, Fei Wang, Dong You, Weiquan Gu, Weineng Feng
Cancer Res Treat. 2023;55(3):841-850.   Published online February 13, 2023
DOI: https://doi.org/10.4143/crt.2022.1438
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We aimed to evaluate whether the addition of pemetrexed is effective in improving progression-free survival (PFS) in epidermal growth factor receptor (EGFR)–mutated patients with or without concomitant alterations.
Materials and Methods
This multicenter clinical trial was conducted in China from June 15, 2018, to May 31, 2019. A total of 92 non–small cell lung cancer (NSCLC) patients harboring EGFR-sensitive mutations were included and divided into concomitant and non-concomitant groups. Patients in each group were randomly treated with EGFR–tyrosine kinase inhibitor (TKI) monotherapy or EGFR-TKI combined with pemetrexed in a ratio of 1:1. PFS was recorded as the primary endpoint.
Results
The overall median PFS of this cohort was 10.1 months. There were no significant differences in PFS between patients with and without concomitant and between patients received TKI monotherapy and TKI combined with pemetrexed (p=0.210 and p=0.085, respectively). Stratification analysis indicated that patients received TKI monotherapy had a significantly longer PFS in non-concomitant group than that in concomitant group (p=0.002). In concomitant group, patients received TKI combined with pemetrexed had a significantly longer PFS than patients received TKI monotherapy (p=0.013). Molecular dynamic analysis showed rapidly emerging EGFR T790M in patients received TKI monotherapy. EGFR mutation abundance decreased in patients received TKI combined chemotherapy, which supports better efficacy for a TKI combined chemotherapy as compared to TKI monotherapy. A good correlation between therapeutic efficacy and a change in circulating tumor DNA (ctDNA) status was found in 66% of patients, supporting the guiding role of ctDNA minimal residual disease (MRD) in NSCLC treatment.
Conclusion
EGFR-TKI monotherapy is applicable to EGFR-sensitive patients without concomitant alterations, while a TKI combined chemotherapy is applicable to EGFR-sensitive patients with concomitant alterations. CtDNA MRD may be a potential biomarker for predicting therapeutic efficacy.

Citations

Citations to this article as recorded by  
  • SP3-induced Timeless transcription contributes to cell growth of lung adenocarcinoma cells
    Ping Tian, Dajun Du, Li Yang, Nan Zhou, Ling Tao, Divijendra Natha Reddy Sirigiri
    PLOS ONE.2024; 19(2): e0298295.     CrossRef
  • PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities
    Xiaohong Liu, Wuxuan Mei, Pengfei Zhang, Changchun Zeng
    Pharmacological Research.2024; 202: 107123.     CrossRef
  • Risk factors for interstitial lung disease in patients with non-small cell lung cancer with epidermal growth factor receptor-tyrosine kinase inhibitors: A systematic review and meta-analysis
    Yosuke Fukuda, Yoshitaka Uchida, Koichi Ando, Ryo Manabe, Akihiko Tanaka, Hironori Sagara
    Respiratory Investigation.2024; 62(3): 481.     CrossRef
  • Concomitant genomic features stratify prognosis to patients with advanced EGFR mutant lung cancer
    Xiao Liang, Jiali Xu, Yuqin Jiang, Yuqian Yan, Hongshuai Wu, Jiali Dai, Yanan Cui, Chen Zhang, Wei Chen, Zhihong Zhang, Renhua Guo
    Molecular Carcinogenesis.2024; 63(9): 1643.     CrossRef
  • Identification and Application of Emerging Biomarkers in Treatment of Non-Small-Cell Lung Cancer: Systematic Review
    Juan Carlos Restrepo, Darly Martínez Guevara, Andrés Pareja López, John Fernando Montenegro Palacios, Yamil Liscano
    Cancers.2024; 16(13): 2338.     CrossRef
  • 4,567 View
  • 262 Download
  • 4 Web of Science
  • 5 Crossref
Close layer
Palliative medicine
Knockdown of EMMPRIN (OX47) in MRMT-1 Carcinoma Cells Inhibits Tumor Growth and Decreases Cancer-Induced Bone Destruction and Pain
Yanke Chen, Jing Luan, Ting Jiang, Donghui Cai, Chao Sun, Xiaofei Wang, Xiaoge Zhao, Xingchun Gou
Cancer Res Treat. 2021;53(2):576-583.   Published online October 29, 2020
DOI: https://doi.org/10.4143/crt.2020.801
AbstractAbstract PDFPubReaderePub
Purpose
Bone destruction and pain caused by cancer is one of the most devastating complications of cancer patients with bone metastases, and it seriously affects the quality of patients’ life. Extracellular matrix metalloproteinase inducer (EMMPRIN) is a cell adhesion molecule with increased expression in a variety of tumors. This study focused to clarify the specific function of EMMPRIN in bone metastasis of breast cancer.
Materials and Methods
Adenovirus with shRNA-EMMPRIN was transfected into MRMT-1 rat breast carcinoma cells, and the MRMT-1 cells with different expression levels of EMMPRIN were implanted into the bone marrow cavity of rat tibia. Next, the effect of down-regulation of EMMPRIN was evaluated as follows: bone damage was detected by X-ray radiological and tartrate-resistant acid phosphatase staining; the tumor burden was evaluated by hematoxylin and eosin staining; the test of pain-related behaviors was assessed used the bilateral paw withdrawal mechanical threshold; and the levels of secretory factors in tumor conditioned medium were determined by using enzyme-linked immunosorbent assay.
Results
We found that down-regulation of EMMPRIN in tumor cells can simultaneously reduce tumor burden, relieve cancer-induced bone destruction and pain.
Conclusion

Materials and Methods
EMMPRIN is expected to be a therapeutic target for relieving bone metastasis of breast cancer and alleviating cancerinduced bone destruction and pain. The method of targeting EMMPRIN may be a promising strategy for the treatment of cancer in the future.

Citations

Citations to this article as recorded by  
  • Matrix metalloproteinases as attractive therapeutic targets for chronic pain: A narrative review
    Xin-Yi Dai, Lin Liu, Fan-He Song, Shao-Jie Gao, Jia-Yi Wu, Dan-Yang Li, Long-Qing Zhang, Dai-Qiang Liu, Ya-Qun Zhou, Wei Mei
    International Journal of Biological Macromolecules.2024; 261: 129619.     CrossRef
  • The role and pharmacological properties of P2Y12 receptor in cancer and cancer pain
    Jia-ling Hu, Wen-jun Zhang
    Biomedicine & Pharmacotherapy.2023; 157: 113927.     CrossRef
  • Cav3.2 T-Type calcium channels downregulation attenuates bone cancer pain induced by inhibiting IGF-1/HIF-1α signaling pathway in the rat spinal cord
    Qingying Liu, Zhongyuan Lu, Huan Ren, Lijun Fu, Yueliang Wang, Huilian Bu, Minyu Ma, Letian Ma, Chen Huang, Jian Wang, Weidong Zang, Jing Cao, Xiaochong Fan
    Journal of Bone Oncology.2023; 42: 100495.     CrossRef
  • 5,908 View
  • 116 Download
  • 3 Web of Science
  • 3 Crossref
Close layer
CXCL-13 Regulates Resistance to 5-Fluorouracil in Colorectal Cancer
Guolin Zhang, Xin Luo, Wei Zhang, Engeng Chen, Jianbin Xu, Fei Wang, Gaoyang Cao, Zhenyu Ju, Dongai Jin, Xuefeng Huang, Wei Zhou, Zhangfa Song
Cancer Res Treat. 2020;52(2):622-633.   Published online December 31, 2019
DOI: https://doi.org/10.4143/crt.2019.593
AbstractAbstract PDFPubReaderePub
Purpose
5-Fluorouracil (5-Fu) is used as a conventional chemotherapy drug in chemotherapy for patients with advanced colorectal cancer, but many patients still suffer from treatment failure due to 5-Fu resistance. Emerging observations revealed the important role of chemokine (C-X-C motif) ligand 13 (CXCL-13) in tumor microenvironment and its relationship with prognosis in patients with colorectal cancer. This study is designed to reveal the important role of CXCL-13 in causing colorectal cancer resistance to 5-Fu.
Materials and Methods
CXCL-13 levels of patient's serum or cell culture supernatants were measured separately by enzyme-linked immunosorbent assay. In cell assays, cell viability is detected by Cell Counting Kit-8. Therefore, the recombinant human CXCL-13 was used to simulate its high expression in cells while its antibody and siRNA were used to reduce CXCL-13 expression in cells.
Results
In this study, we demonstrated that CXCL-13 is associated with 5-Fu resistance by culture medium exchange experiments and cytokine arrays of colorectal cancer resistant and nonresistant cells. Clinical studies showed that CXCL-13 is highly expressed in the serum of 5-Fu–resistant patients. High levels of serum CXCL-13 also predict a worse clinical outcome. The addition of recombinant CXCL-13 cytokine resulted in 5-Fu resistance, while its antibody overcame 5-Fu resistance, and knockdown of CXCL-13 expression by siRNA also reduced 5-Fu resistance, which can be saved by added recombination CXCL-13.
Conclusion
These results not only identify a CXCL-13 mediated 5-Fu resistance mechanism but also provide a novel target for 5-Fu–resistant colorectal cancer in prevention and treatment strategies.

Citations

Citations to this article as recorded by  
  • Nucleotide metabolism-associated drug resistance gene NDUFA4L2 promotes colon cancer progression and 5-FU resistance
    Hongxin HE, Shiyao ZHENG, Shangkun JIN, Weijie HUANG, Enhao WEI, Shen GUAN, Chunkang YANG
    Scientific Reports.2025;[Epub]     CrossRef
  • Mechanism of 5-fluorouracil induced resistance and role of piperine and curcumin as chemo-sensitizers in colon cancer
    Dorothy Bhattacharjya, Nageswaran Sivalingam
    Naunyn-Schmiedeberg's Archives of Pharmacology.2024; 397(11): 8445.     CrossRef
  • The combination of SHP099 inhibits the malignant biological behavior of L-OHP/5-FU-resistant colorectal cancer cells by regulating energy metabolism reprogramming
    Meilian Wang, Kun Yu, Wen Fu, Lihong Yang
    Biochemical and Biophysical Research Communications.2024; 728: 150262.     CrossRef
  • Serum CXCL13 as a Novel Biomarker in Oral Squamous Cell Carcinoma
    Shin Tojo, Koh‐ichi Nakashiro, Nobuyuki Kuribayashi, Daisuke Uchida
    Cancer Medicine.2024;[Epub]     CrossRef
  • The potential of kaempferol in digestive system tumors: recent advances and mechanistic insights
    Xunxing Hao, Meng Ding, Chenyu Chi, Xiaodong Xu, Xiaoyu Zhang, Mingzhe Hu
    Discover Oncology.2024;[Epub]     CrossRef
  • Identification of a tissue resident memory CD8 T cell-related risk score signature for colorectal cancer, the association with TME landscapes and therapeutic responses
    Jiazheng Li, Chao Yang, Yongbin Zheng
    Frontiers in Genetics.2023;[Epub]     CrossRef
  • Prognostic Significance of the CXCLs and Its Impact on the Immune Microenvironment in Ovarian Cancer
    Cairu Gu, Xifeng Xiong, Wei Liu, Elisa Belluzzi
    Disease Markers.2023; 2023: 1.     CrossRef
  • TIMP-2 as a predictive biomarker in 5-Fu-resistant colorectal cancer
    Yaoqing Li, Chuchu Xu, Renjun Zhu, Liyijing Shen, Gengyuan Hu, Kelong Tao, Feng Tao, Zengxin Lu, Guolin Zhang
    Journal of Cancer Research and Clinical Oncology.2023; 149(10): 7235.     CrossRef
  • Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes
    Katharine Yu, Amrita Basu, Christina Yau, Denise M. Wolf, Hani Goodarzi, Sourav Bandyopadhyay, James E. Korkola, Gillian L. Hirst, Smita Asare, Angela DeMichele, Nola Hylton, Douglas Yee, Laura Esserman, Laura van ‘t Veer, Marina Sirota
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Host Transcriptional Regulatory Genes and Microbiome Networks Crosstalk through Immune Receptors Establishing Normal and Tumor Multiomics Metafirm of the Oral-Gut-Lung Axis
    Beatriz Andrea Otálora-Otálora, Juan Javier López-Rivera, Claudia Aristizábal-Guzmán, Mario Arturo Isaza-Ruget, Carlos Arturo Álvarez-Moreno
    International Journal of Molecular Sciences.2023; 24(23): 16638.     CrossRef
  • Expansion of CD4+ cytotoxic T lymphocytes with specific gene expression patterns may contribute to suppression of tumor immunity in oral squamous cell carcinoma: single-cell analysis and in vitro experiments
    Hu Chen, Junsei Sameshima, Shiho Yokomizo, Tomoki Sueyoshi, Haruki Nagano, Yuka Miyahara, Taiki Sakamoto, Shinsuke Fujii, Tamotsu Kiyoshima, Thomas Guy, Seiji Nakamura, Masafumi Moriyama, Naoki Kaneko, Shintaro Kawano
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Identification of Key Gene Targets for Sensitizing Colorectal Cancer to Chemoradiation: an Integrative Network Analysis on Multiple Transcriptomics Data
    Hamed Manoochehri, Akram Jalali, Hamid Tanzadehpanah, Amir Taherkhani, Massoud Saidijam
    Journal of Gastrointestinal Cancer.2022; 53(3): 649.     CrossRef
  • Exosomes-mediated tumor treatment: One body plays multiple roles
    Na Xu, Ranran Guo, Xiaotong Yang, Ning Li, Jia Yu, Peng Zhang
    Asian Journal of Pharmaceutical Sciences.2022; 17(3): 385.     CrossRef
  • Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer
    Ching-Hung Hsieh, Cheng-Zhe Jian, Liang-In Lin, Guan-Sian Low, Ping-Yun Ou, Chiun Hsu, Da-Liang Ou
    Cancers.2022; 14(2): 294.     CrossRef
  • Comprehensive analysis of the expression and significance of CXCLs in human diffuse large B-cell lymphoma
    Xiaonan Zhou, Shizhu Guo, Yonghong Shi
    Scientific Reports.2022;[Epub]     CrossRef
  • Kaempferol Can Reverse the 5-Fu Resistance of Colorectal Cancer Cells by Inhibiting PKM2-Mediated Glycolysis
    Haili Wu, Jin’e Du, Chenglu Li, Hanqing Li, Huiqin Guo, Zhuoyu Li
    International Journal of Molecular Sciences.2022; 23(7): 3544.     CrossRef
  • Chemokines and chemokine receptors in colorectal cancer; multifarious roles and clinical impact
    Maria Braoudaki, Mohammed Saqif Ahmad, Denis Mustafov, Sara Seriah, Mohammad Naseem Siddiqui, Shoib Sarwar Siddiqui
    Seminars in Cancer Biology.2022; 86: 436.     CrossRef
  • Bioinformatics Analysis of Prognostic Significance and Immune Characteristics of CXC Chemokine Family in Patients with Lung Adenocarcinoma
    Dachen Bian, Yanhua Chen, Ahmed Faeq Hussein
    Computational and Mathematical Methods in Medicine.2022; 2022: 1.     CrossRef
  • Chemokines in progression, chemoresistance, diagnosis, and prognosis of colorectal cancer
    Qian Zou, Xue Lei, Aijing Xu, Ziqi Li, Qinglian He, Xiujuan Huang, Guangxian Xu, Faqing Tian, Yuanlin Ding, Wei Zhu
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • CXCL13-CXCR5 axis: Regulation in inflammatory diseases and cancer
    Binhan Wang, Manni Wang, Danyi Ao, Xiawei Wei
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2022; 1877(5): 188799.     CrossRef
  • A novel oxidative stress- and ferroptosis-related gene prognostic signature for distinguishing cold and hot tumors in colorectal cancer
    Xu Wang, Yuanmin Xu, Longfei Dai, Zhen Yu, Ming Wang, Shixin Chan, Rui Sun, Qijun Han, Jiajie Chen, Xiaomin Zuo, Zhenglin Wang, Xianyu Hu, Yang Yang, Hu Zhao, Kongwang Hu, Huabing Zhang, Wei Chen
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • Identification of necroptosis-related subtypes, development of a novel signature, and characterization of immune infiltration in colorectal cancer
    Mengyu Sun, Xiaoyu Ji, Meng Xie, Xiaoping Chen, Bixiang Zhang, Xiangyuan Luo, Yangyang Feng, Danfei Liu, Yijun Wang, Yiwei Li, Bifeng Liu, Limin Xia, Wenjie Huang
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • Recent Updates on Mechanisms of Resistance to 5-Fluorouracil and Reversal Strategies in Colon Cancer Treatment
    Shamin Azwar, Heng Fong Seow, Maha Abdullah, Mohd Faisal Jabar, Norhafizah Mohtarrudin
    Biology.2021; 10(9): 854.     CrossRef
  • CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer
    Sipei Nie, Yicong Wan, Hui Wang, Jinhui Liu, Jing Yang, Rui Sun, Huangyang Meng, Xiaolin Ma, Yi Jiang, Wenjun Cheng
    Journal of Ovarian Research.2021;[Epub]     CrossRef
  • The CXCL Family Contributes to Immunosuppressive Microenvironment in Gliomas and Assists in Gliomas Chemotherapy
    Zeyu Wang, Yuze Liu, Yuyao Mo, Hao Zhang, Ziyu Dai, Xun Zhang, Weijie Ye, Hui Cao, Zhixiong Liu, Quan Cheng
    Frontiers in Immunology.2021;[Epub]     CrossRef
  • Multifaceted roles of CCL20 (C-C motif chemokine ligand 20): mechanisms and communication networks in breast cancer progression
    Louis Boafo Kwantwi, Shujing Wang, Youjing Sheng, Qiang Wu
    Bioengineered.2021; 12(1): 6923.     CrossRef
  • CXCL13 in Cancer and Other Diseases: Biological Functions, Clinical Significance, and Therapeutic Opportunities
    San-Hui Gao, Sheng-Zhi Liu, Gui-Zhen Wang, Guang-Biao Zhou
    Life.2021; 11(12): 1282.     CrossRef
  • Therapeutic Influence on Important Targets Associated with Chronic Inflammation and Oxidative Stress in Cancer Treatment
    Margarita Neganova, Junqi Liu, Yulia Aleksandrova, Sergey Klochkov, Ruitai Fan
    Cancers.2021; 13(23): 6062.     CrossRef
  • Chemoresistance Mechanisms in Colon Cancer: Focus on Conventional Chemotherapy
    Klara Mladenić , Mirela Sedić
    Clinical Cancer Drugs.2021; 8(2): 67.     CrossRef
  • 12,331 View
  • 347 Download
  • 29 Web of Science
  • 29 Crossref
Close layer
Novel Prognostic Nomograms Based on Inflammation-Related Markers for Patients with Hepatocellular Carcinoma Underwent Hepatectomy
Yifei Wang, Kaiyu Sun, Jingxian Shen, Bin Li, Ming Kuang, Qinghua Cao, Sui Peng
Cancer Res Treat. 2019;51(4):1464-1478.   Published online March 11, 2019
DOI: https://doi.org/10.4143/crt.2018.657
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Hepatocellular carcinoma (HCC) is an aggressive disease with high recurrence rate. However, current staging systems were lack of predictive capacity for HCC recurrence. We aimed to develop prognostic nomograms based on inflammation-related markers for HCC patients underwent hepatectomy.
Materials and Methods
We recruited 889 surgically treated patients from two medical centers. Independent prognostic factors were identified by cox regression analyses. Nomograms for recurrence-free survival (RFS) and overall survival (OS) were established, and validated internally and externally. The performance, discrimination, and calibration of nomograms were assessed, and compared with existed staging systems.
Results
Neutrophil to lymphocyte ratio (NLR) and gamma-glutamyl transpeptidase to platelet ratio (GPR) were the two inflammation-related factor that independently correlated with survival. NLR, GPR, international normalized ratio (INR), microvascular invasion, satellite lesions, tumour number, tumour diameter, and macrovascular invasion were used to construct nomogram for RFS while GPR, total bilirubin, INR, α-fetoprotein, microvascular invasion, satellite lesions, tumour diameter, and macrovascular invasion were for OS. In the training cohort, the C-index of nomogram was 0.701 (95% confidence interval [CI], 0.669 to 0.732) for RFS and 0.761 (95% CI, 0.728 to 0.795) for OS. These results received both internal and external validation with C-index of 0.701 (95% CI, 0.647 to 0.755) and 0.707 (95% CI, 0.657 to 0.756) for RFS, and 0.706 (95% CI, 0.640 to 0.772) and 0.708 (95% CI, 0.646 to 0.771) for OS, respectively. The nomograms showed superior accuracy to conventional staging systems (p<0.001).
Conclusion
The nomograms based on inflammation-related markers are of high efficacy in predicting survival of HCC patients after hepatectomy, which will be valuable in guiding postoperative interventions and follow-ups.

Citations

Citations to this article as recorded by  
  • A Dynamic Online Nomogram Based on Gd-EOB-DTPA-Enhanced MRI and Inflammatory Biomarkers for Preoperative Prediction of Pathological Grade and Stratification in Solitary Hepatocellular Carcinoma: A Multicenter Study
    Fei Wang, Yuan Qin, Zheng ming Wang, Chun yue Yan, Ying He, Dan Liu, Li Wen, Dong Zhang
    Academic Radiology.2024; 31(10): 4021.     CrossRef
  • Development and comprehensive validation of a predictive prognosis model for very early HCC recurrence within one year after curative resection: a multicenter cohort study
    Lei Liu, Shangdong Qin, Kongying Lin, Qingguo Xu, Yuan Yang, Jinzhen Cai, Yongyi Zeng, Shengxian Yuan, Bangde Xiang, Wan Yee Lau, Weiping Zhou
    International Journal of Surgery.2024;[Epub]     CrossRef
  • Prognostic nomogram based on the gamma-glutamyl transpeptidase-to-platelet ratio for patients with compensated cirrhotic hepatocellular carcinoma after local ablation
    Wenying Qiao, Jiashuo Li, Peiyi Wang, Yuanyuan Zhang, Ronghua Jin, Jianjun Li
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • A Novel Risk-Predicted Nomogram for Perioperative Ischemic Complications of Endovascular Treatment Among Ruptured Anterior Communicating Artery Aneurysms
    Wei Shang, Xiaoting Chang, Yousong Xu, Bin Dong
    World Neurosurgery.2023; 173: e391.     CrossRef
  • Time to surgery is not an oncological risk factor in HCC patients undergoing liver resection
    Carlos Constantin Otto, Guanwu Wang, Anna Mantas, Daniel Heise, Philipp Bruners, Sven Arke Lang, Tom Florian Ulmer, Ulf Peter Neumann, Lara Rosaline Heij, Jan Bednarsch
    Langenbeck's Archives of Surgery.2023;[Epub]     CrossRef
  • Inflammation-related nomogram for predicting survival of patients with unresectable hepatocellular carcinoma received conversion therapy
    Jia-Lin Wu, Jun-Yang Luo, Zai-Bo Jiang, Si-Bo Huang, Ge-Run Chen, Hui-Ying Ran, Qi-Yue Liang, Ming-Sheng Huang, Li-Sha Lai, Jun-Wei Chen
    World Journal of Gastroenterology.2023; 29(20): 3168.     CrossRef
  • Prognostic impact of gamma-glutamyl transpeptidase to platelets ratio on hepatocellular carcinoma patients who have undergone surgery: a meta-analysis and systematic review
    Yang Zhang, Fangfang Jin, Yuan Wu, Bingyu Wang, Jingri Xie, Yu Li, Yujia Pan, Zhaolan Liu, Wenjuan Shen
    European Journal of Gastroenterology & Hepatology.2023; 35(8): 803.     CrossRef
  • Estimating surgical probability: Development and validation of a prognostic model for patients with lumbar disc herniation treated with acupuncture
    Di Chen, Zimeng Lv, Yicheng Wu, Panfu Hao, Liu Liu, Bin Pan, Haiping Shi, Youlu Che, Bo Shen, Peng Du, Xiaohua Si, Zhongling Hu, Guorui Luan, Mingxin Xue
    Medicine.2023; 102(48): e36425.     CrossRef
  • Clinical significance of Osaka prognostic score based on nutritional and inflammatory status in patients with esophageal squamous cell carcinoma
    Jifeng Feng, Lifen Wang, Liang Wang, Xun Yang, Guangyuan Lou
    BMC Cancer.2022;[Epub]     CrossRef
  • Pathologic Complete Response Prediction to Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Real-World Evidence from Integrative Inflammatory and Nutritional Scores
    Jifeng Feng, Liang Wang, Xun Yang, Qixun Chen, Xiangdong Cheng
    Journal of Inflammation Research.2022; Volume 15: 3783.     CrossRef
  • Serum levels of inflammatory markers CRP, ESR and albumin in relation to survival for patients with hepatocellular carcinoma
    Hikmet Akkiz, Brian I. Carr, Harika G. Bag, Ümit Karaoğullarından, Kendal Yalçın, Nazim Ekin, Ayşegül Özakyol, Engin Altıntaş, Hatice Y. Balaban, Halis Şimşek, Ahmet Uyanıkoğlu, Ayhan Balkan, Sedef Kuran, Oğuz Üsküdar, Yakup Ülger, Burak Güney, Anil Delik
    International Journal of Clinical Practice.2021;[Epub]     CrossRef
  • Development and validation of a nomogram to predict the mortality risk in elderly patients with ARF
    Junnan Xu, Jie Weng, Jingwen Yang, Xuan Shi, Ruonan Hou, Xiaoming Zhou, Zhiliang Zhou, Zhiyi Wang, Chan Chen
    PeerJ.2021; 9: e11016.     CrossRef
  • A new model based on gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts prognostic outcome after curative resection of solitary hepatocellular carcinoma
    Dongye Yang, Hongliang Wu, Wenxiong Nong, Min Zheng, Angui Li, Yang Wang, Mu Li, Qian Chen, Shengguang Yuan, Junxiong Yu, Weijia Liao
    Clinics and Research in Hepatology and Gastroenterology.2021; 45(5): 101509.     CrossRef
  • Naples Prognostic Score: A Novel Prognostic Score in Predicting Cancer-Specific Survival in Patients With Resected Esophageal Squamous Cell Carcinoma
    Ji-Feng Feng, Jian-Ming Zhao, Sheng Chen, Qi-Xun Chen
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Development of pre and post‐operative nomograms to predict individual survival for ideal liver resection candidates with hepatocellular carcinoma
    Jinshu Zeng, Jianxing Zeng, Jingfeng Liu, Jinhua Zeng
    Liver International.2021; 41(12): 2974.     CrossRef
  • Development and validation of prognostic nomograms in patients with hepatocellular carcinoma: a population-based study
    Youya Zang, Peiyun Long, Ming Wang, Shan Huang, Chuang Chen
    Future Oncology.2021; 17(36): 5053.     CrossRef
  • Albumin-Bilirubin (ALBI) and Monocyte to Lymphocyte Ratio (MLR)-Based Nomogram Model to Predict Tumor Recurrence of AFP-Negative Hepatocellular Carcinoma
    Shuqi Mao, Xi Yu, Yuying Shan, Rui Fan, Shengdong Wu, Caide Lu
    Journal of Hepatocellular Carcinoma.2021; Volume 8: 1355.     CrossRef
  • Prognostic Nomogram for Patients with Radical Surgery for Non-Metastatic Colorectal Cancer Incorporating Hematological Biomarkers and Clinical Characteristics


    Peiyun Long, Youya Zang, Huan Wang, Xiumei Liang, Xuekun Xie, Zhiwei Han, Dongyi Lin, Zongyu Wang, Shan Huang, Chuang Chen
    OncoTargets and Therapy.2020; Volume 13: 2093.     CrossRef
  • Novel Prognostic Nomograms for Predicting Early and Late Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy


    Wei Xu, Ruineng Li, Fei Liu
    Cancer Management and Research.2020; Volume 12: 1693.     CrossRef
  • Dynamic Changes in the Neutrophil-to-Lymphocyte Ratio Predict the Prognosis of Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization


    Hongyu Wang, Chuyang Lin, Wenzhe Fan, Jiang Zhang, Yingqiang Zhang, Wang Yao, Jiaping Li
    Cancer Management and Research.2020; Volume 12: 3433.     CrossRef
  • Combination of preoperative neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio: a superior prognostic factor of endometrial cancer
    Rong Cong, Fanfei Kong, Jian Ma, Qing Li, Qijun Wu, Xiaoxin Ma
    BMC Cancer.2020;[Epub]     CrossRef
  • Predictive value of preoperative and postoperative peripheral lymphocyte difference in hepatitis B virus‐related hepatocellular cancer patients: Based on the analysis of dynamic nomogram
    Dingan Luo, Haoran Li, Heng Yu, Mao Zhang, Jianchong Hu, Cheng Jin, Meisze Chua, Bing Han
    Journal of Surgical Oncology.2020; 122(8): 1553.     CrossRef
  • Development and validation of a prognostic model based on the albumin-to-fibrinogen ratio (AFR) and gamma-glutamyl transpeptidase-to-platelet ratio (GPR) in hepatocellular carcinoma patients
    Jinfu Zhang, Tao Wang, Liangliang Xu, Peng Wang, Ming Zhang, Mingqing Xu
    Clinica Chimica Acta.2020; 511: 107.     CrossRef
  • Prognostic Nomograms for Patients with Hepatocellular Carcinoma After Curative Hepatectomy, with a Focus on Recurrence Timing and Post-Recurrence Management


    Wei Xu, Fei Liu, Xianbo Shen, Ruineng Li
    Journal of Hepatocellular Carcinoma.2020; Volume 7: 233.     CrossRef
  • Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics
    Quirino Lai, Alessandro Vitale, Tommaso Manzia, Francesco Foschi, Giovanni Levi Sandri, Martina Gambato, Fabio Melandro, Francesco Russo, Luca Miele, Luca Viganò, Patrizia Burra, Edoardo Giannini
    Cancers.2019; 11(10): 1568.     CrossRef
  • 10,078 View
  • 267 Download
  • 20 Web of Science
  • 25 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP